- Home
- ICU vs CNSP Comparison
ICU vs CNSP Comparison
Compare ICU & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICU | CNSP |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ICU | CNSP |
|---|---|---|
| Price | $4.94 | $5.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 115.7K | 12.9K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.00 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.80 |
| 52 Week High | $5.38 | $10.59 |
Technical Indicators
Market Signals| Indicator | ICU | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 71.29 | 61.34 |
| Support Level | $2.32 | $5.15 |
| Resistance Level | N/A | $5.61 |
| Average True Range (ATR) | 0.42 | 0.37 |
| MACD | 0.25 | 0.09 |
| Stochastic Oscillator | 83.06 | 95.48 |
Price Performance
Historical ComparisonAbout ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.